Vetoquinol has reported a 50.6% increase in net income to €32 million for the first six months of 2023, with operating income before non-recurring items of €39 million, representing a margin of 15.1% of sales.

The animal health laboratory posted sales of €256 million, down 5.4% on a reported basis and 4.6% at constant exchange rates, with its 'Essentials' products business accounting for €151 million (-1.1% at constant exchange rates).

Vetoquinol adds that it "has the solid fundamentals (strong operating profitability, cash flow generation, no debt) to pursue its development strategy, and the means to finance its external growth ambitions".

Copyright (c) 2023 CercleFinance.com. All rights reserved.